BioSpace

Have you read Annalee Armstrong's story about her visit to Nusano's new radioisotope facility? Here are some fun details about her visit.

Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval. #rarediseases #biospace https://hubs.li/Q04h71TK0

Takeda's announcement last week that it will axe about 4,500 employees makes May the most brutal month so far for biopharma layoffs in 2026—and the month isn’t even over. #layoffs #biopharma #biospace https://hubs.li/Q04h6VfD0

BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth. #rarediseases #biospace https://hubs.li/Q04h6Xjn0

Despite having no definitive data, Sen. Ron Johnson (R-WI) in a letter to health secretary Robert F. Kennedy, Jr. suggested there was a conscious effort by the Biden administration’s FDA to cover up the safety risks of COVID-19 vaccines. #vaccines #FDA #biospace https://hubs.li/Q04h5DsZ0

Merck and Kelun-Biotech's antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to file for approval. #ADC #pharma #biospace https://hubs.li/Q04h5Knb0

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation. #biotech #bigpharma #biospace https://hubs.li/Q04h5Bxl0

BioSpace examines how the FDA approval of Eli Lilly and Company's oral obesity drug Foundayo has ignited a key race with Novo Nordisk. #FDA #obesity #bispace https://hubs.li/Q04h1rcQ0

A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter. #drugdevelopment #oncology #biospace https://hubs.li/Q04g-LpY0

Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline. #pharma #biospace https://hubs.li/Q04g-JPh0